Research Article
Serum Interleukin 17 Levels in Patients with Crohn’s Disease: Real Life Data
Table 1
Baseline characteristics and laboratory values of patients with Crohn’s disease and control subjects.
| | | Crohn’s disease | Control group | |
| | Age median (min.–max.) years | 38.5 (18–63) | 39 (22–60) | 0.84 | | Gender (female/male) | 25/25 | 21/19 | 0.81 | | Montreal classification (%) | | | | | L1 (isolated ileal disease) | 21 | — | | | L2 (isolated colonic disease) | 2 | — | | | L3 (ileocolonic disease) | 27 | — | | | L4 (concomitant UGI disease) | 0 | — | | | B1 (nonstricturing and nonpenetrating) | 29 | — | | | B2 (stricturing) | 3 | — | | | B3 (penetrating) | 18 | — | | | CDAI median (min.–max.) | 124.5 (1–394) | — | | | Treatment (%) | | | | | Mesalazine | 46 (92%) | — | | | Corticosteroid | 11 (22%) | — | | | Azathioprine | 27 (54%) | — | | | Methotrexate | 1 (2%) | — | | | Anti-TNF | 12 (24%) | — | | | White blood cells (/mm3) | | | 0.60 | | Hemoglobin (g/dL) | | | 0.13 | | Platelets (/mm3) | | | 0.01 | | Glucose (mg/dL) | | | 0.35 | | Blood urea nitrogen (mg/dL) | | | 0.42 | | Creatinine (mg/dL) | | | 0.56 | | ALT (U/L) | | | 0.13 | | Albumin (g/dL) | | | <0.01 | | ESR (mm/hour) | | | 0.01 | | CRP (mg/dL) | | | 0.03 | | IL17 (ng/L) | | | 0.14 |
|
|
